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Abstract
Ovarian cancer is the most lethal gynaecological cancer and is often diagnosed in late stage, often as the result of the
unavailability of sufficiently sensitive biomarkers for early detection, tumour progression and tumour-associated
inflammation. Glycosylation is the most common posttranslational modification of proteins; it is altered in cancer and
therefore is a potential source of biomarkers. We investigated the quantitative and qualitative effects of anti-inflammatory
(acetylsalicylic acid) and pro-inflammatory (thioglycolate and chlorite-oxidized oxyamylose) drugs on glycosylation in mouse
cancer serum. A significant increase in sialylation and branching of glycans in mice treated with an inflammation-inducing
compound was observed. Moreover, the increases in sialylation correlated with increased tumour sizes. Increases in
sialylation and branching were consistent with increased expression of sialyltransferases and the branching enzyme MGAT5.
Because the sialyltransferases are highly conserved among species, the described changes in the ovarian cancer mouse
model are relevant to humans and serum N-glycome analysis for monitoring disease treatment and progression might be a
useful biomarker.
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Introduction
Ovarian cancer is the fifth most common cancer in females and
the second most common gynaecological cancer. Although it is the
most lethal of all gynaecological cancers among women in Europe
[1], early diagnosis can considerably prolong life expectancy and
quality of life. However, most patients are diagnosed when the
disease is in an advanced stage [2]. The 5-year survival rate, which
is more than 90% for early stage diagnosis, decreases in advanced
stages to only about 30% [2]. Currently ovarian cancer patients
are subjected to CT scans and CA125 levels to monitor disease
recurrence or progression, but these tests are frequently not
sensitive and specific enough to detect the cancer in early stages
[3]. More sensitive tests, such as the presence of cancer-specific
serum biomarkers are urgently needed and to this end we have
investigated the use of specific N-glycans from serum. Changes in
glycosylation are found in many cancers and inflammatory
conditions such as acute and chronic inflammatory diseases
(sepsis, pancreatitis, rheumatoid arthritis, diabetes) and infection
[4]. The most common glycosylation alterations to N-glycans in
cancer and chronic inflammatory conditions are increases in
sialylation, branching and fucosylation [5,6].
Inflammation and infection increase the risk of ovarian cancer
[7]. Inflammation has been found to be one of the critical
processes that govern cancer biology following experiments
showing that inflammatory cells, cytokines and chemokines
contribute to tumour growth and progression [8,9]. Consequently,
non-steroidal anti-inflammatory drugs reduce the risk of cancer,
decrease cell growth, induce apoptosis and inhibit the survival of
cancer cells [7,10,11]. Chlorite-oxidized oxyamylose (COAM) is
an antiviral agent effective in the treatment of virus-induced
cancer and in a model of mammary cancer in C3H mice [12,13].
Recently, it was demonstrated that COAM is a pro-inflammatory
drug, inducing and binding chemokines [14,15].
The aim of this study was to investigate whether changes occur
in N-glycosylation with anti- and pro-inflammatory drug treat-
ments in a tumour-bearing host, whether a correlation exists with
tumour size and whether this can be analyzed in serum samples as
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a useful biomarker. We have based our study on the mouse
experimental model in which tumour size was found to be
increased with pro- and decreased with anti-inflammatory drugs
and in which macrophages had a significant influence on tumour
progression [16]. We have analysed mouse serum samples using
our fully quantitative high-throughput N-glycan analysis based on
high performance liquid chromatography (HPLC)-separation of
glycans released from the serum.
Materials and Methods
Reagents
COAM was synthesized by a two-step oxidation of amylose by
the method described by Claes et al. [17], analyzed for endotoxin
contamination by the Limulus amebocyte lysate test (Cambrex Bio
Science, Verviers, Belgium) and quality-controlled as described
[18]. COAM was dissolved in phosphate-buffered saline (PBS) and
stored at 220uC. For working solutions, the PBS stocks were
diluted in endotoxin-free saline (0.9% NaCl, Baxter, Braine-
l’Alleud, Belgium) to the desired concentration.
Xenogeneic ovarian carcinoma model
OVCAR3 adenocarcinoma cells (ATCC Number HTB-161)
were grown as monolayer cultures in stationary flasks (75 cm2) in
RPMI 1640 medium (Lonza, Verviers, Belgium) with 4 mM
glutamine, supplemented with 10%(v/v) heat-inactivated foetal
calf serum (FCS) and penicillin/streptomycin at 37uC in an
atmosphere of 5%CO2. The animal experiments were approved
by the ethical committee of the University of Leuven. The
experimental ovarian carcinoma tumour model [16] involved the
resuspension of 16107 OVCAR3 cells in PBS/Matrigel (1:1) in a
total volume of 0.5 mL. This suspension was injected on day 0 into
the peritoneum of female C.B-17/lcr severe combined immuno-
deficient (scid/scid) mice (8–12 weeks) which were bred and
housed under specific pathogen-free conditions. The injected mice
were divided into different groups for each experiment. One group
(n = 5) was treated with acetylsalicylic acid (ASA, 100 mg/kg in
PBS; pH5.0) by daily s.c. injection, one group (n= 5) with
thioglycolate (TG) broth (0.5 mL of a 3% solution, Fluka-Sigma-
Aldrich, Bornem, Belgium) by i.p. treatment twice per week, and
one group (n = 5) with COAM (2 mg in PBS, pH neutral) by i.p.
injection once per week. Control mice were administered PBS s.c.
(pH 5.0, daily, n = 5) or i.p. (neutral pH, twice per week, n= 5). A
separate group (n= 5) was injected with tumour cells but
maintained without a weekly peritoneal lavage procedure. An
additional group of mice (n = 4) did not receive tumour cells, nor
peritoneal lavage. The weekly peritoneal lavages comprised the
injection of 4 mL of ice-cold PBS (with 2% FCS and 20 U/mL
heparin) into the peritoneum of anaesthetized mice. The
peritoneum was gently massaged during 1 min, and the fluid
was retrieved and pooled per treatment group. Seven weeks after
OVCAR3 cell injection, all mice were sacrificed and the tumour
foci were collected and counted. The tumour diameters were
measured by use of a caliper. The tumour volumes were evaluated
with the formula (4pab2)/3, with a and b the largest and smallest
radii, respectively. Blood was collected from individual mice by
retro-orbital puncture and incubated for 1 h at room temperature,
followed by 6 h at 4uC to obtain serum. Serum was collected upon
two centrifugations of 8 min at 1100 rpm and stored at 280uC
until glycan analyses. The in vivo experiment was performed twice.
Flow cytometry analysis
Flow cytometry analysis was performed weekly to characterize
peritoneal cell populations. Peritoneal cell suspensions were
centrifuged and the collected cells were resuspended and
erythrocytes were lysed in lysis buffer (0.15 M NH4Cl, 1.0 mM
KHCO3, 0.1 mM Na2EDTA, pH 7.2, 3 min incubation, 37uC).
The lysis process was stopped by addition of fluorescent-activated
cell sorting (FACS) buffer (PBS with 2%FCS). The remaining cells
were washed twice and resuspended. Cell numbers were counted.
Single-cell suspensions (0.12–0.56106 living cells) were passed
through nylon meshes (tubes with cell-strainer cap, BD Falcon,
Erembodegem, Belgium), washed in 500 mL FACS buffer and
incubated for 15 min with Fc receptor-blocking antibodies
(0.5 mL/0.56106 cells; anti-mouse CD16/CD32; Miltenyi Biotec,
Bergisch Gladbach, Germany). After a wash step with FACS
buffer, cells were stained for markers of different innate immune
cell types with the indicated fluorophore-conjugated antibodies
(eBioscience, San Diego, CA) during minimally 20 min. Washed
cells were fixed with 0.4%formaldehyde in PBS. Alternatively, for
staining of apoptotic and necrotic cells, the Annexin-V-FLUOS
Staining Kit (Roche Applied Science, Vilvoorde, Belgium) was
applied on non-fixed cells. Cells were analyzed on a FACSCalibur
flow cytometer (between 5,000 and 20,000 events being acquired)
and data were processed with CellQuest software (Becton
Dickinson Immunocytometry Systems, San Jose, CA).
N-glycan analysis
N-glycans were released from 5 ml sera using a high-throughput
method [19]. Briefly, samples were reduced and alkylated in 96-
well plates, set into SDS-gel blocks and washed. The N-linked
glycans were released using peptide N-glycanase F (1000 U/ml;
EC3.5.1.52) [20,21] and labelled by reductive amination with the
2-aminobenzamide [20] (Ludger TagTM 2-AB glycan labelling kit,
Ludger Ltd, Oxford, UK).
The 2-AB-labelled glycans were digested in 10 mL of 50 mM
sodium acetate buffer, pH5.5 for 18 h at 37uC, using arrays of the
following enzymes (Prozyme, San Leandro, CA, USA) at the
indicated concentrations: Arthrobacter ureafaciens sialidase
(EC3.2.1.18), 1 U/mL; Streptococcus pneumoniae sialidase
(EC3.2.1.18), 1 U/mL; coffee bean a-galactosidase (EC3.2.1.22),
25 U/ml; bovine testes b-galactosidase (EC3.2.1.23), 1 U/mL;
Streptococcus pneumoniae b-galactosidase (EC3.2.1.23), 0.1 U/mL;
jack bean b-N-acetylhexosaminidase (EC3.2.1.24), 50 U/mL;
bovine kidney a-fucosidase (EC3.2.1.51), 1 U/mL; almond meal
a-fucosidase (EC3.2.1.111), 3 mU/mL; Xanthomonus sp. a-fucosi-
dase (EC3.2.1.51.), 0.1 U/ml; jack bean a-mannosidase
(EC3.2.1.24), 50 U/mL and b-N-acetylglucosaminidase cloned
from Streptococcus pneumonia, expressed in E. coli (EC 3.2.1.30), 4 U/
mL. After incubation, enzymes were removed by filtration through
protein-binding EZ filters (Millipore Corporation) [22].
Hydrophilic interaction liquid chromatography (HILIC) HPLC
was performed using a TSK-Gel Amide-80 4.66250 mm column
(Anachem, Luton, Bedfordshire, UK) on a 2695 Alliance
separations module (Waters, Milford, MA) and a Waters 2475
fluorescence detector. Solvent A was 50 mM formic acid adjusted
to pH4.4 with ammonia solution. Solvent B was acetonitrile. The
column temperature was set to 30?C. The 60 minutes high-
throughput method was used: a linear gradient of 35–47% solvent
A over 48 min at a flow rate of 0.8 mL/min, followed by 1 min at
47–100%A and 4 min at 100%A, returning to 35%A over 1 min
and then finishing with 35%A for 6 min [19]. Samples were
injected in 80% acetonitrile [22]. The system was calibrated using
an external standard of hydrolyzed and 2-aminobenzamide-
labelled glucose oligomers to create a dextran ladder [22].
Weak anion exchange (WAX)-HPLC was performed using a
Vydac 301VHP575 7.5650-mm column (Anachem) on a 2695
Alliance separations module with a Waters 474 fluorescence
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detector. Solvent A was 0.5 M formic acid adjusted to pH9.0 with
ammonia solution, and solvent B was 10% (v/v) methanol in
water. Gradient conditions were as follows: a linear gradient of 0–
5%A over 12 min at a flow rate of 1 mL/min, followed by 5–
21%A over 13 min and then 21–50% A over 25 min, 80–100% A
over 5 min, and then 5 min at 100%A. Samples were injected in
water. A fetuin N-glycan standard was used for calibration [22].
Sialic acid analysis
Sialic acids were released and derivatized with 1,2-diamino-4,5-
methylenedioxybenzene according to the manufacturer’s instruc-
tions (Ludger, Abingdon, UK) [23]. The labelled samples were
analysed using reversed phase HPLC on a Waters XBridge
BEH C18 15062.1 mm i.d., 3.5 mm column with fluorescence
detection.
Electrospray (ESI) mass spectrometry
N-glycans were released from the glycoproteins with PNGase F
as described above and cleaned with a Nafion membrane [24].
Samples were dissolved in water:methanol (1:1, v:v) containing
0.1 M ammonium phosphate and infused into the nanospray ion
source of a Waters quadrupole-time-of-flight Ultima Global
instrument (Waters, Manchester, UK) using Proxeon nanospray
capillaries (Thermo Fisher Scientific, UK) The ion source
conditions were: temperature, 120uC; nitrogen flow 50 L/hr;
infusion needle potential, 1.2 kV; cone voltage 100 V; RF-1
voltage 150 V. Negative ion mass spectrometry (MS) and collision-
induced dissociation spectra (2 sec scans) were acquired with a
digitization rate of 4 GHz and accumulated until a satisfactory
signal:noise ratio had been obtained. For MS/MS data acquisi-
tion, the parent ion was selected at low resolution (about 4 m/z
mass window) to allow transmission of isotope peaks and
fragmented with argon. The voltage on the collision cell was
adjusted with mass and charge to give an even distribution of
fragment ions across the mass scale. Typical values were 80–
120 V. Other voltages were as recommended by the manufactur-
er. Instrument control, data acquisition and processing were
performed with MassLynx software Version 4.0. Ions were
detected as phosphate adducts and spectral interpretation was as
described in reference [25]. Desialylation of the N-glycans for mass
spectrometric analysis was performed by heating 1 mL of an
aqueous solution with 1 mL of 1% acetic acid for 30 mins at 80uC.
Quantitative PCR (qPCR)
Total RNA from mouse livers was extracted using the RNeasyH
RNA isolation kit (Qiagen, Hilden, Germany) including on-
column DNase digestion. RNA yield and purity were determined
spectrophotometrically and by denaturing agarose gel electropho-
resis, respectively. Single-stranded cDNA was synthesised from
1.5 mg of total RNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems Inc, Foster City, CA).
Primers and probe sequences for the endogenous gene TBP
(reference Mm00446973_m1*) and the genes ST3Gal1
(Mm00501493_m1*), ST3Gal3 (Mm00493353_m1*), ST3Gal4
Figure 1. COAM-treated mice have significantly higher cell numbers, tumour volumes and numbers of neutrophils, macrophages
and necrosis. A Total numbers of recovered viable intraperitoneal leukocytes per pool in each group (treated with COAM, ASA, TG, PBS (i.p. or s.c.);
Cell counts determined in Bu¨rker chambers (in the presence of trypan blue exclusion of dead cells), represented as mean counts per mouse. B
Tumour volume per mouse at 7 weeks after tumour cell inoculation; *p,0.05. C Flow cytometry data represent absolute cell counts of pooled
peritoneal cells per group (indicated as mean number per mouse, 5 mice per group): CD11B+/Gr-1+ neutrophils, CD11B+/F4/80+ macrophages and
necrotic cells, as determined by propidium iodide and annexinV analysis.
doi:10.1371/journal.pone.0071159.g001
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(Mm00501503_m1*), ST3Gal6 (Mm00450665_m1*), ST6Gal1
(Mm00486119_m1*), MGAT5 (Mm00455036_m1*) were pre-
designed TaqManTM Gene Expression Assays from Applied
Biosystems-Applera Hispania SA, Spain. All PCRs reactions were
performed in optical 96-well plates with an ABI PRISM 7300
Sequence Detector System in a total volume of 20 ml containing
9 ml of cDNA diluted in RNAse free water, 10 ml of TaqManH
Universal Master Mix No AmpEraseH and 1 ml of the corre-
sponding Custom Taqman Gene Expression AssayTM. The
following standard thermal profile was used for all PCRs: 95uC
for 10 min; 40 cycles of 95uC for 15 s and 60uC for 1 min and
data were analysed with 7300 SDS 1.3.1 software (Applied
Biosystems). The relative concentrations of the genes were
calculated by the comparative Ct Method (DDCts). TBP was used
as a reference gene to normalize the results. The data for each
mouse comprises the mean6SD of four replicates. The data for
each mouse group corresponds to the mean6SD of the data for
the four mice in that group (N= 16). Normality of data (x) was
tested using the Kolmogorov-Smirnov test and the homogeneity of
variances was checked using the Levene’s test. The differences
between data (all with normal distribution and homogenous
variances) were analysed using the parametric Student’s t test. The
criterion for significance was set at p,0.01.
Statistical Analysis
Statistical analysis of the data was performed using using the
SPSS statistical software for Windows (version 15 and 19; SPSS
Inc., Chicago, IL). The data are compositional, since they convey
relative rather than absolute quantities. Therefore, we transform
the data using the logit transformation. Thus, each variable is of
the form log(peak/(1-peak)).
Repeated measures analysis was used to determine the change
in glycosylation over time and between groups. A repeated
measures model was fitted for the logit transform of each glycan
peak. The Greenhouse Geisser adjustment was used to account for
non-homogeneity of variance across groups. The p-values were
corrected for multiple testing error, using the false discovery rate
(FDR) approach proposed by Benjamini and Hochberg [26]. An
adjusted p,0.05 was considered statistically significant.
Pearson’s correlation was applied for correlation analyses
(normal distribution).
Results
Tumour model
OVCAR3 cells in PBS/Matrigel were injected intraperitoneally
in female C.B-17/lcr (scid/scid) mice of 8–12 weeks on day 0. We
investigated influences of tumour progression and drug treatments
on the serum glycome in six randomized cohorts: group 1 mice
treated sc with ASA; group 2 mice treated with PBS (control for
group 1, PBS sc); group 3 mice treated ip with TG; group 4 mice
treated with PBS (control for groups 3 and 5, PBS ip); group 5
mice treated ip with COAM; group 6 mice not treated, only
intraperitoneal injection of OVCAR3 tumor cells and group 7
consisted of mice with no tumour (blank). The blood samples were
taken from all mice every week for seven weeks. ASA was
administered daily by subcutaneous injection, whereas TG was
administered intraperitoneally twice per week and COAM once
per week. Therefore, two control groups were established which
were treated with PBS in exactly the same way as the COAM and
ASA groups.
Tumour volume and immunological profiles
Total numbers of recovered viable intraperitoneal leukocytes
per group were counted weekly for each treatment group and at
the end of the seventh week, tumour volumes were measured in all
Figure 2. Typical HILIC- (A) and WAX-HPLC (B) chromatograms of mouse serum N-glycans. Structural assignments are in Table 1 and
Figure S1. The HILIC-chromatogram was separated into 19 peaks and the WAX-chromatogram was separated into 5 peaks: S1, S2, S3A, S3B and S4.
Symbols encode the following monosaccharide structures: GlcNAc, filled square; mannose, open circle; galactose, open diamond; fucose, diamond
with a dot inside; Neu5Gc sialic acid, star with dot inside; beta linkage, solid line; alpha linkage, dotted line (Harvey et al [36]).
doi:10.1371/journal.pone.0071159.g002
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groups (Figure 1A–B). COAM-treated mice showed significantly
higher cell numbers and tumour volumes than all other
experimental groups (*p,0.05, Figure 1A–B).
The panels in Figure 1C show peritoneal cell populations. In
line with previous data about cellular effects of COAM after
intraperitoneal injection [14], in the COAM-treated group,
significantly higher numbers of neutrophils (CD11b+ and high
levels of GR-1 membrane staining) were consistently observed
over the 7 week period of the experiment. Macrophage numbers
were also consistently increased by COAM and also gradually
increased from the third week onwards by treatment with ASA.
Cell necrosis remained at high levels in the COAM groups,
whereas it gradually decreased to basis levels in the other
treatment groups (Figure 1C).
Mouse serum N-glycome characterization
Total serum N-glycans from all mice samples were analysed by
HILIC- and WAX-HPLC, combined with exoglycosidase diges-
tions with structural assignments made using database matching
(GlycoBase; glycobase.nibrt.ie). Assignments were also confirmed
by negative ion electrospray MS [25]. N-glycans were separated by
WAX-HPLC first and then each peak was run on HILIC-HPLC
and structures were assigned with exoglycosidase digestions.
Serum N-glycans were separated into 19 peaks on HILIC-
HPLC (Figure 2A) and into 5 peaks on WAX-HPLC (Figure 2B).
A summary of all N-glycans from mouse serum is shown in Table 1
and 2 and detailed analysis in Figure S1. The whole mouse N-
glycome contained low levels of non-sialylated glycans as well as
monosialylated, disialylated biantennary, trisialylated triantennary
and biantennary, and tetrasialylated triantennary glycans (Table 1).
Triantennary glycans were branched at the 6-antenna (b1,6-
branching, Figure S2).
All peaks in all samples were plotted to monitor whether a trend
of different progression or significant differences existed among
groups vide infra.
Increased sialylation and branching indicates the
presence of ovarian tumours in mice and pro-
inflammatory drugs significantly alter these glycosylation
changes
Serum N-glycomes from untreated mice carrying tumour and
mice without tumour (blank) were compared. HILIC-HPLC
profiles show decreases in high mannosylated and monosialylated
glycans that indicates tumour presence (Table 3).
N-glycomes from ASA-, TG- [16] and COAM-treated [14,15]
mice were compared to control mice.
No significant differences were observed after ASA-treatment.
In TG- and COAM-treated mice, both HILIC- and WAX-HPLC
showed an increase in highly sialylated and branched glycans and
a decrease in less branched and sialylated glycans, indicating an
increase in branching and sialylation with TG- and COAM-
treatment (Table 4 and 5). These changes were more significant
with COAM-administration, where almost the complete N-
glycome was affected (Table 5).
Table 1. Summary of mouse serum N-glycome.
Peak GU ESI1 m/z Abbreviation2
1 6.16 1331.6a M5
2 6.99 1493.5a M6
1581.5b A1G(4)1S(6)1
3 7.39 1784.6b A2G(4)1S(6)1
4 7.80 1743.6b M4A1G(4)1S(6)1
5 8.24 1946.7b A2G(4)2S(6)1
6 8.47 – A1G(4)1S(6,6)2
7 8.76 1905.6b M5A1G(4)1S(6)1
2092.7b FA2G(4)2S(6)1
8 8.88 2253.8b,2275.7b,c,1126.4d,1186.3c,e A2G(4)2S(3)2
9 9.34 2253.8b,2275.7b,c,1126.4d,1186.3c,e A2G(4)2S(3,6)2
2399.8b,2421.8b,c,1199.4d,1259.4c,e FA2G(4)2S(3)2
1979.6a M9
10 9.78 2253.8b,2275.7b,c,1126.4d,1186.3c,e A2G(4)2S(6)2
1199.4d,1259.4c,e FA2G(4)2S(3,6)2
11 10.21 1199.4d FA2G(4)2S(6)2
1279.9d,1290.9c,e A2G(3,4)2S(3,3,6)3
12 10.53 1279.9d,1290.9d A2G(3,4)2S(3,6,6)3
1352.9d,1363.9c,e FA2G(3,4)2S(3,3,6)3
13 10.85 1352.9d,1363.9c,e FA2G(3,4)2S(3,6,6)3
14 11.16 1462.5d,1473.5c,e A3G(4)3S(3)3
15 11.41 1462.5d,1473.5c,e A3G(4)3S(3,3,6)3
16 11.63 1462.5d,1473.5c,e A3G(4)3S(3,6,6)3
1535.5d,1546.5c,e FA3G(4)3S(3,3,6)3
17 11.92 1535.5d,1546.5c,e FA3G(4)3S(3,6,6)3
1616.0d,1627.0c,e,1638.1e,f A3G(3,4,4)3S(3,3,3,6)4
18 12.26 1627.0d,1638.0c,e A3G(3,4,4)3S(3,3,6,6)4
1689.1d,1700.2c,e FA3G(3,4,4)3S(3,3,3,6)4
19 12.54 1689.1d,1700.2c,e FA3G(3,4,4)3S(3,6,6,6)4
S1 – monosialylated
S2 – disialylated biantennary
S3A – trisialylated triantennary
S3B – trisialylated biantennary
S4 – tetrasialylated triantennary
1Various ions:
aSingly charged ion ([M+H2PO4]2),
bSingly charged ion ([M-H]2),
cSodium salt,
dDoubly charged ion ([M-2H]22),
eDoubly charged ion ([M-H+H2PO4]22),
fDi-sodium salt.
2All N-glycans have two core GlcNAcs; Mx = high-mannose where x = the
number of mannose residues, D = substitution position of high-mannose
glycans, Ax = number of antennae, Gx = number of galactose residues,
Sx = number of sialic acids, F = core fucose. The linkage positions of the
galactose and sialic acid residues are given in parentheses (Royle et al [19]).
doi:10.1371/journal.pone.0071159.t001
Table 2. Masses and structures of the N-glycans after
desialylation with acetic acid.
m/z Abbreviation1
MALDI ([M+Na]+) ESI ([M+H2PO4]2)
1501.7 1575.5 A2G(4)1
1666.6 1737.6 A2G(4,4)2
1809.6 1883.7 FA2G(4)2
2028.7 2102.7 A3G(4)3
doi:10.1371/journal.pone.0071159.t002
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Increases in sialylation in serum glycoproteins are
associated with tumour progression
After the changes in the serum N-glycomes from mice in each
group were identified, tumour volumes were correlated with the N-
glycomes. Both HILIC- and WAX-HPLC showed a decrease in
disialylated and an increase in trisialylated glycans and WAX-
HPLC also showed an increase in tetrasialylated glycans that
correlated with increased tumour size (Figure 3, Table S1).
We have further looked into sialylation in these samples and also
expression of enzymes responsible for branching and sialylation on
mouse glycans.
Sialic acid analysis shows high proportions of
glycolylneuraminic acid and no observed changes
among the treatment groups
Sialic acids from mice sera were examined. Samples contained
mostly N-glycolylneuraminic acid (Figure S3). There were no
observed correlations in the proportions of the sialic acid species
with treatments or tumour volumes. Murine HILIC peaks eluted
at higher GUs than human glycans because of the presence of
Neu5Gc instead of Neu5Ac and probably also due to the linkages
of some sialic acids to GlcNAc [27,28,29]. Also sialidase digestions
on some samples required higher amount of the enzyme
suggesting a less accessible linkage of sialic acid on GlcNAc
compared with Gal.
Expression of glycosyltransferases in mouse liver shows
consistence in increasing sialylation and branching with
tumour and pro-inflammatory COAM administration
The expression of several glycosyltransferases related to
branching and sialylation was analysed in the livers from treated
and untreated mice and mice without tumour (blank).
The presence of the tumour is associated with up-regulated
a1,6-mannosylglycoprotein b1,6-N-acetylglucosaminyltransferase5
(MGAT5) by 3.4-fold and several a2,3-siayltransferases that
transfer a2,3-sialic acid on terminal galactose, ST3Gal1 (2,3-fold),
ST3Gal3 (4.2-fold) and ST3Gal6 (3.1-fold), as well as an increase
in the expression of a2,6-sialtransferase1 (ST6Gal1) by 4.4-fold
(Figure 4). ST3Gal1 transfers a2,3-sialic acid onto Gal-b1-
3GalNAc on O-glycans and glycolipids, ST3Gal3 acts on Gal-
b1-3(4)GlcNAc, ST3Gal6 acts on Galb1-4GlcNAc and ST6Gal1
acts on Gal-b1-4GlcNAc on N- or O-glycans. As a result, an
increase in branching and sialylation on the liver glycoproteins
from tumour-bearing mice was expected on the basis of these
expression changes. Indeed, the overexpression of those sialyl-
transferases was consistent with the increase in sialylation in
tumour-bearing mice.
Livers from COAM-treated mice showed an overexpression of
MGAT5 by 2.4-fold and ST3Gal1 in 3.7-fold compared to
controls (Figure 4). This is consistent with the increase in
branching on N-glycans from these mice. The increase in
sialylation could be explained by the up-regulation of MGAT5,
which gives rise to b1,6-branching, which was found present on
triantennary glycans (Figure S2). This new branch could be
extended with terminal galactose residues that may be sialylated
and thus lead to an increase in tri- and tetrasialylated glycans.
The expression of all sialyltransferases and MGAT5 was
significantly increased in the tumour bearing mice compared to
mice without tumours (blank) (Figure 4).
Discussion
In a previous pre-clinical ovarian carcinoma study, related to
inflammation and cancer, TG was used as an inflammatory
stimulus to elicit peritoneal macrophages [16]. We here used the
same animal model and compared COAM with TG and observed
that (i) COAM is a more potent pro-inflammatory activator of
peritoneal myeloid cells and (ii) its effects on glycosylation of serum
proteins was more extended than those observed with TG. In
addition, we provide a means of monitoring tumour progression
by measuring serum glycome markers. We also provide a general
approach monitoring the effect of tumour-associated inflammation
on disease progression and serum marker alterations. COAM
Table 3. Average % glycan values of significantly altered peaks between untreated tumour-bearing mice versus mice without
tumours (blank).
HILIC
Peak2 Peaks
M6+A1G(4)1S(6)1 Abbreviation
Group 7 Group 6 Group
1.43 1.60 Week 0 Average values of % peak areas
in group
A Untreated tumour-bearing
mice versus mice without
tumours (blank)
1.10 1.09 Week 1
1.50 1.18 Week 2
1.59 1.53 Week 3
1.14 1.24 Week 4
1.15 1.10 Week 5
1.44 1.25 Week 6
1.24 1.131 Week 7
0.889 Group FDR adjusted P-value
Q0.020 Progression
Significant p-values are highlighted in bold (p,0.05) (peak 2 is significantly decreased).
doi:10.1371/journal.pone.0071159.t003
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induces and binds chemokines in such a way that these molecules
remain chemotactically active [14,15]. The bound chemokines, for
instance GCP-2/CXCL6, exert a potent neutrophil chemotaxis in
the mouse [30]. Myeloid cells, depending on their polarization,
have dual effects on cancer progression [31]. In this study, we
observed by FACS analysis the presence of myeloid cells, both
neutrophils and macrophages (Figure 1C). The induction of both
types of myeloid cells by COAM was corroborated in the
peritoneal cavity, where the ovarian cancer progressed. Increased
neutrophil-mediated inflammation, induced by COAM, which
correlated with increased tumour volume (Figure 1b) adds essential
complementary information to previous findings that anti-inflam-
matory drugs reduce the risk of cancer [7,10]. The tumour-
associated neutrophils, depending on their stimulation state and
micro-environment, may have pro- or anti-tumoural effects [31].
Recently, we detected an early anti-tumoural effect of COAM and
neutrophils in a syngenic melanoma mouse model. As the
melanoma model progressed, the effect of COAM at later tumour
developmental stages was not beneficial [15]. Together with the
present data, this seems to indicate that prolongation of neutrophil
influx into tumors, such as was observed in tumours with higher
neutrophil chemokine levels, helps in tumour progression and is
detrimental for the host [31].
Sialylation and branching increases with administration
of pro-inflammatory drugs and with tumour progression
We observed significant increases in sialylation and branching
on glycans in mice treated with pro-inflammatory compounds,
such as COAM and TG (Table 4 and 5). These changes in
glycosylation were more significantly pronounced in case of
COAM administration compared to TG. Tumour volume
significantly increased with COAM administration, whereas only
slightly with TG treatment (Figure 1b). We hypothesize that this
may be explained by the following sequence of events. Firstly,
inflammatory agents such as cytokines from the tumour promote
the expression of liver glycoproteins such as acute phase proteins
with altered glycosylation [32]. Then the resulting inflammatory
response promotes tumour growth, therefore the changes in
glycosylation may precede the changes in tumour volumes. Also,
we observed increases in sialylation that correlated with increased
tumour size (Figure 3). These effects were detected in serum
samples, instead of biopsies. Therefore they indicate that, in the
future such analysis might constitute a patient-compliant way for
monitoring ovarian cancer.
Several publications report changes in glycosylation in cancer
and inflammatory conditions in mouse models. Lin et al. found
significant increases in internal a2,6-sialylation in colon and
breast tumours and substitution of N-glycolylneuraminic acid for
Figure 3. Serum glycoprotein sialylation significantly increases with tumour volume. Significant correlations of tumour volume with
HILIC- (A) and WAX- (B)-peaks. Data represent mean peak %area per mouse, 5 mice per group.
doi:10.1371/journal.pone.0071159.g003
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N-acetylneuraminic acid in colonic tumour using matrix-assisted
laser desorption/ionization (MALDI)-MS [28]. Lattova et al.
described increase in high mannose glycans and hybrid glycans,
core-fucosylated and disialylated core-fucosylated glycans in head
and neck tumours also using MALDI-MS [33]. Yasukawa et al.
observed increase in a2,3- and a2,6-sialylation and a2,3- and
a2,6-sialyltransferases using lectins and RT-PCR in inflammation
[34]. Itoh et al. found increases in a1,6-fucose and a2,6-
fucosyltransferase in diabetic mice using HPLC of pyridineami-
nated glycans and RT-PCR [35].
Glycosyltransferases in liver correspond to observed
increases in sialylation and branching with tumour and
pro-inflammatory drugs administration
We identified several glycosyltransferases responsible for sialyla-
tion and branching of glycans attached to serum glycoproteins that
were consistently expressed in mouse liver tissue. MGAT5,
responsible for branching, was significantly increased in mice
with tumours compared with those without, as well as in mice
treated with pro-inflammatory COAM (Figure 4). Several
sialyltransferases were increased in the tumor-bearing mice too,
including a2,3-sialtransferases ST3Gal1, ST3Gal3 and ST3Gal6
as well as a2,6-sialtransferase1 ST6Gal1. Increase in ST3Gal1,
ST3Gal3 and ST6Gal1 in the tumour-bearing hosts is consistent
with data from Yasukawa et al. who found these enzymes also
increased in mouse liver after turpentine-induced inflammation
[34].
Conclusions
Association of cancer and inflammation has been discussed for
decades. Non-steroidal anti-inflammatory drugs were found to be
protective and reduce the risk of cancer, decrease cell growth,
induce apoptosis and inhibit the survival of cancer cells [7,10,11].
Therefore, here the mechanism of anti-inflammatory drugs
limiting cancer progression appears to be through modulating
the inflammatory response which is tightly connected to carcino-
genesis. This is the first report of a direct correlation between
glycosylation changes in the cancer serum glycome and inflam-
mation as well as with treatments altering the inflammatory
process in a relevant tumour model of ovarian cancer. Also, this is
the first report describing the influence of COAM on tumour-
associated inflammation, tumour progression and glycosylation in
cancer sera. Overall, this study provides the description of an
animal model and method to begin to study the mechanisms and
effects of immune system modulators on glycan and glycoprotein
changes on tumor biology. We introduce the novel method of
looking at potential effects from tumour associated inflammatory
Figure 4. Sialyltransferases and branching enzyme levels significantly increase in tumour-bearing mice and with COAM-treatment.
Plotted is the relative mRNA expression of glycosyltransferase enzymes in mouse liver in four mouse groups (Untreated tumour-bearing mice
compared to mice without the tumour (blank) and COAM-treated mice compared to control (PBS ip)). *p,0.01; Bars indicate standard deviation of
four independent experiments which were comprised of four replicates each.
doi:10.1371/journal.pone.0071159.g004
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signalling on liver released glycans and glycoproteins. The changes
we have described in the serum glycome correlate with tumour
progression and could serve as potentially useful serum biomarkers
for monitoring cancer progression and response to therapy.
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